Skip to main content
SpringerLink
Log in

Pharmacokinetics of Calcium Antagonists Under Development

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Calcium antagonist drugs under clinical development are of the Type I (verapamil, diltiazem-like) and Type II (nifedipine-like) classes: Tiapamil, the only Type I drug currently available, is a high clearance, widely distributed drug which undergoes extensive presystemic elimination. Pharmacokinetically it is quite similar to verapamil; however, it does have increased biliary excretion and decreased binding to plasma proteins. Eight Type II (dihydropyridine) drugs are reviewed. Seven of these drugs (felodipine, isradipine, nicardipine, nilvadipine, nimodipine, nisoldipine and nitrendipine) are pharmacokinetically similar to nifedipine, with high clearance, extensive distribution, and significant presystemic elimination. Amlodipine has lower clearance, even greater peripheral distribution, and greatly decreased presystemic elimination. Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.

Unlike nifedipine, each dihydropyridine drug under development has an asymmetric centre; therefore each in fact is a racemic mixture. Human pharmacokinetic and pharmacodynamic data have not been reported for any of the racemates.

Each of the drugs has been studied in patients with hepatic and renal disease. Predictably, patients with severe hepatic disease have decreased presystemic clearance and, in some cases decreased clearance after intravenous administration of the dihydropyridines, although renal failure has little influence on their pharmacokinetics. Unfortunately, disease-drug interaction studies of this class of drugs do not generally report plasma protein binding.

The effect of age on the disposition of 2 of the dihydropyridines has been reported; however, only for nicardipine can a conclusion be drawn, namely that volume of distribution may increase with age and clearance may remain unchanged. A variety of potential drug-drug interactions have been evaluated, most commonly the effect of these drugs on cardiac glycoside disposition and effect, and the effect of cimetidine on the disposition of dihydropyridines. Tiapamil, like verapamil, impairs digoxin clearance significantly. Among the dihydropyridines, although minor pharmacokinetic effects have in some cases been reported, the magnitude of the interactions suggest they have limited clinical importance.

From drugs currently under development, it is clear that a large number of calcium antagonists will soon be introduced into clinical use. Only 1 of the newer drugs, amlodipine, has significant pharmacokinetic differences from the agents currently in use, although possible pharmacodynamic differences among the drugs have been suggested. Further study will be necessary to determine if the therapeutic spectrum of calcium antagonist drugs will be significantly broadened with the introduction of these developmental agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahr G, Graefe K-H, Wingender W, Schmitz H. Steady-state pharmacokinetics of nisoldipine after i.v. infusion in healthy volunteers. Naunyn-Schmiedeberg’s Archives of Pharmcology 334 (Suppl.): R55, 1986

    Google Scholar 

  • Allen JC. The current status of the mechanism of the calcium channel antagonists. Progress in Cardiovascular Diseases 25: 133–140, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ariëns EJ, Wuis EW. Bias in pharmacokinetics and clinical pharmacology. Clinical Pharmacology and Therapeutics 42: 361–363, 1987

    Article  PubMed  Google Scholar 

  • Aronoff GR. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. Journal of Cardiovascular Pharmacology 6 (Suppl. 7): S974–S976, 1984

    PubMed  CAS  Google Scholar 

  • Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, et al. Long-acting dihydropyridine calcium antagonists I: 2-alkoxymethyl derivatives incorporating basic substituents. Journal of Medical Chemistry 29: 1696–1702, 1986

    Article  CAS  Google Scholar 

  • Benet LZ, Galeazzi RL. Noncompartmental determination of steady-state volume of distribution. Journal of Pharmaceutical Sciences 68: 1071–1074, 1979

    Article  PubMed  CAS  Google Scholar 

  • Boelaert J, Valcke Y, Dammekens H, De Vriese G, Schurgers M, et al. The pharmacokinetics of nisoldipine in patients with renal dysfunction. Nisoldipine Workshop, Luxembourg, 1986

    Google Scholar 

  • Breimer DD, Lodewijks MThM, van Brummelen P, van Harten J, Wilson JPH. Pharmacokinetics and haemodynamic effects of nisoldipine in patients with liver cirrhosis. British Journal of Pharmacology 89 (Suppl.): 482P, 1986

    Google Scholar 

  • Brown SD, Freedman D, DeVault GA, Slay L (Elderly Multicenter Study Group). Safety, efficacy and pharmacokinetics of nicardipine in elderly hypertensive patients. British Journal of Clinical Pharmacology 22: 289S–295S, 1986

    Article  Google Scholar 

  • Clair F, Bellet M, Guerret M, Drueke T, Grunfeld JP. Hypotensive effect and pharmacokinetics of nicardipine in patients with severe renal failure. Current Therapeutic Research 28: 74–82, 1985

    Google Scholar 

  • Dow RJ, Graham DJM. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. British Journal of Clinical Pharmacology 22: 195S–202S, 1986

    Article  CAS  Google Scholar 

  • Drayer DE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clinical Pharmacology and Therapeutics 40: 125–133, 1986

    Article  PubMed  CAS  Google Scholar 

  • Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M. The effect of dextro, levo, and racemic verapamil on atrioventricular conduction in man. American Heart Journal 109: 210–217, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem. Clinical Pharmacokinetics 11: 425–449, 1986

    Article  PubMed  CAS  Google Scholar 

  • Echizen H, Vogelgesang B, Eichelbaum M. Effects of d, 1-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clinical Pharmacology and Therapeutics 38: 71–76, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Edgar B, Hoffmann J-J, Lundborg P, Regardh C-G, Rönn O, et al. Absorption, distribution, and elimination of felodipine in man. Drugs 29 (Suppl. 2): 9–15, 1985b

    Article  PubMed  Google Scholar 

  • Edgar B, Regardh CG, Johnsson G, Johnsson L, Lundborg P, et al. Felodipine kinetics in healthy men. Clinical Pharmacology and Therapeutics 38: 205–211, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum J, Mikus G, Vogelgesang B. Pharmacokinetics of (+), (−), and (±)-verapamil after intravenous administration. British Journal of Clinical Pharmacology 17: 453–458, 1984

    Article  PubMed  CAS  Google Scholar 

  • Faulkner JL, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. British Journal of Clinical Pharmacology 22: 21–25, 1986

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein A. History of calcium antagonists. Circulation Research 52:(Suppl. 1): 3–16, 1983

    CAS  Google Scholar 

  • Forette F, Bellet M, Henry JF, Hervy MP, Poyard-Salmeron C, et al. Effect of nicardipine in elderly hypertensive patients. British Journal of Clinical Pharmacology 20: 125S–129S, 1985

    Article  PubMed  Google Scholar 

  • Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. Journal of Clinical Pharmacology 23: 161–170, 1983

    PubMed  CAS  Google Scholar 

  • Gengo FM, Fagan SC, Krol G, Bernhard H. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. British Journal of Clinical Pharmacology 23: 47–53, 1987

    Article  PubMed  CAS  Google Scholar 

  • Giacomini JC, Nelson WL, Wong FM, Rood D, Giacomini KM. Stereo-selective pharmacodynamics of verapamil. Clinical Research 32: 241A, 1984

    Google Scholar 

  • Goa KL, Sorkin EM. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 33: 123–155, 1987

    Article  PubMed  CAS  Google Scholar 

  • Graham DJM, Dow RJ, Freedman D, Mroszczak E, Ling T. Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgraduate Medical Journal 60 (Suppl. 4): 7–10, 1984

    PubMed  CAS  Google Scholar 

  • Graham DJM, Dow RJ, Hall DJ, Alexander OF, Mroszczak RJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. British Journal of Clinical Pharmacology 20: 23S–28S, 1985

    Article  PubMed  CAS  Google Scholar 

  • Higuchi S, Saseki H, Seki T. Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans. Xenobiotica 10: 897–903, 1980

    Article  PubMed  CAS  Google Scholar 

  • Higuchi S, Shiobara Y. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10: 889–896, 1980

    Article  PubMed  CAS  Google Scholar 

  • Hinderling PH, Eckert M, Gasic S, Eichler HG, Potzi R, et al. Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis. European Journal of Clinical Pharmacology 31: 397–404, 1986

    Article  PubMed  CAS  Google Scholar 

  • Karliner JS, Motulsky HJ, Dunlop J, Brown JH, Insel PA. Verapamil competitively inhibits alpha-1 adrenergic and muscarinic but not beta-adrenergic receptors in rat myocardium. Journal of Cardiovascular Pharmacology 4: 515–520, 1982

    Article  PubMed  CAS  Google Scholar 

  • Kendall MJ, Lobo J, Jack DB, Main ANH. The influence of age on the pharmacokinetics of nitrendipine. Journal of Cardiovascular Pharmacology 9 (Suppl. 4): S96–S100, 1987

    Article  Google Scholar 

  • Kirch W, Dylewicz D, Hutt HJ, Ohnhaus EE. Pharmacokinetics of nitrendipine in liver disease. Journal of Clinical Pharmacology 25: 467, 1985

    Google Scholar 

  • Kirch W, Rämsch KD, Dührsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. International Journal of Clinical Pharmacology Research 5: 381–384, 1984

    Google Scholar 

  • Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clinical Pharmacology and Therapeutics 41: 26–30, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics 35: 742–749, 1984

    Article  PubMed  CAS  Google Scholar 

  • Kleinbloesem CH, van Brummelen P, van Harten J, Danhof M, Breimer DD. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clinical Pharmacology and Therapeutics 37: 563–574, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kuhlmann J, Ziegler R, Wingender W, Rämsch, KD, Ahr G. Beeinflussen nisoldipin, nitrendipin, und nimodipin die pharmakokinetik und wirksamketi von herzglykosiden. Zeitschrift für Kardiologie 75 (Suppl. 4): 78, 1986

    Google Scholar 

  • Lasseter KC, Shamblen EC, Murdoch AA, Burkholder DE, Krol GJ, et al. Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. Journal of Cardiovascular Pharmacology 6 (Suppl. 7): S977–S981, 1984

    PubMed  CAS  Google Scholar 

  • Lee SM, Williams R, Warnock D, Emmett M, Wolbach RA. The effects of nicardipine in hypertensive subjects with impaired renal function. British Journal of Clinical Pharmacology 22: 297S–306S, 1986

    Article  Google Scholar 

  • Lessem J, Bellinetto A. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil. Clinical Therapeutics 5: 595–602, 1983

    PubMed  CAS  Google Scholar 

  • Müller FO, Hundt HKL, Luus HG, Joubert AL, Groenewoud G. Estimation of the bioavailability of nisoldipine in man. Nisoldipine Workshop, Luxembourg, 1986

    Google Scholar 

  • Nayler WG. The heterogeneity of the slow channel blockers (calcium antagonists). International Journal of Cardiology 3: 391–400, 1983

    Article  PubMed  CAS  Google Scholar 

  • Niwa T, Tokuma Y, Noguchi H. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog. Research Communications in Chemical Pathology and Pharmacology 55: 75–88, 1987

    PubMed  CAS  Google Scholar 

  • Pond SM, Tozer TN. First-pass elimination: basic concepts and clinical consequences. Clinical Pharmacokinetics 9: 1–25, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rämsch K-D, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 5 (Suppl. 2): 18–24, 1983

    Google Scholar 

  • Rämsch K-D, Ahr G, Tettenborn D, Auer LM. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirugia 28: 74–78, 1985

    Google Scholar 

  • Rämsch K-D, Graefe K-H, Scherling D, Sommer J, Ziegler R. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. American Journal of Nephrology 6 (Suppl. 1): 73–80, 1986

    PubMed  Google Scholar 

  • Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, et al. The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica 16: 341–349, 1986

    Article  PubMed  CAS  Google Scholar 

  • Saris SD, Porter RS, Lowenthal DT. Effect of chronic vs acute dosing of nitrendipine in chronic liver disease. Clinical Pharmacology and Therapeutics 39: 226, 1986

    Google Scholar 

  • Schwartz JB. Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. Journal of Cardiovascular Pharmacology, in press, 1988

    Google Scholar 

  • Schwartz JB, Abernethy DR, Taylor AA, Mitchel JR. An investigation of the cause of accumulation of verapamil during regular dosing of patients. British Journal of Clinical Pharmacology 19: 512–517, 1985

    Article  PubMed  CAS  Google Scholar 

  • Silke B, Graham DJM, Verma SP, Reynolds G, Frais MA, et al. Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease. European Journal of Clinical Pharmacology 29: 651–657, 1986

    Article  PubMed  CAS  Google Scholar 

  • Singh BN. The mechanism of action of calcium antagonists relative to their clinical applications. British Journal of Clinical Pharmacology 21: 109S–121S, 1986

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH, Reynolds IJ. Calcium antagonist drugs, receptor interactions that clarify therapeutic effects. New England Journal of Medicine 313: 995–1002, 1985

    Article  PubMed  CAS  Google Scholar 

  • Sorkin EM, Clissold SP. Nicardipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension, and related cardiovascular disorders. Drugs 33: 296–345, 1987

    Article  PubMed  CAS  Google Scholar 

  • Terakawa M, Tokuma Y, Shishido A, Noguchi H. Pharmaockinetics of nilvadipine in healthy volunteers. Journal of Clinical Pharmacology 27: 111–117, 1987a

    PubMed  CAS  Google Scholar 

  • Terakawa M, Tokuma Y, Shishido A, Yasuda K, Noguchi H. Effect of two different meals on bioavailability of nilvadipine in healthy volunteers. Journal of Clinical Pharmacology 27: 293–296, 1987b

    PubMed  CAS  Google Scholar 

  • Tucker FA, Minty PSB, MacGregor GA. Study of nifedipine photodecomposition in plasma and whole blood using capillary gas-liquid chromatography. Journal of Chromatography Biomedical Applications 342: 193–198, 1985

    Article  PubMed  CAS  Google Scholar 

  • Urien S, Albengres E, Comte A, Kiechel J-R, Tillement J-P. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. Journal of Cardiovascular Pharmacology 7: 891–898, 1985

    Article  PubMed  CAS  Google Scholar 

  • Van Harten J, Van Brummelen P, Danhof M, Lodewijks MThM, Breimer DD. Pharmacokinetics and haemodynamic effects of nisoldipine and its interaction with cimetidine in healthy volunteers. Acta Pharmacologica et Toxicologica 59 (Suppl. 5, Pt. 1): 180, 1986

    Google Scholar 

  • Van Zwliten PA, Van Meel JCA, Timmermans PBMWM. Pharmacology of calcium entry blockers: interaction with vascular alpha-adrenoceptors. Hypertension 5 (Suppl. II): II–8–II–17, 1983

    Google Scholar 

  • Vinge E, Andersson K-E, Brandt L, Ljunggren B, Nilsron L-G, et al. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid hemorrhage. European Journal of Clinical Pharmacology 30: 421–425, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. British Journal of Clinical Pharmacology 18: 733–740, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wendt B. Pharmacokinetics and metabolism of tiapamil. Cardiology 69 (Suppl. 1): 68–78, 1982

    Article  PubMed  CAS  Google Scholar 

  • Wilkinson GR, Shand DB. A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390, 1975

    PubMed  CAS  Google Scholar 

  • Ziegler R, Wingender W, Boehme K, Raemsch K, Kuhlmann J. Study of pharmacokinetic and pharmacodynamic interaction between nitrendipine and digoxin. Journal of Cardiovascular Pharmacology 9 (Suppl. 4): S101–S106, 1987

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Brown University, Providence, Rhode Island, USA

    Darrell R. Abernethy & Janice B. Schwartz

  2. Departments of Medicine and Pharmacy, University of California, San Francisco, California, USA

    Darrell R. Abernethy & Janice B. Schwartz

Authors
  1. Darrell R. Abernethy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janice B. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abernethy, D.R., Schwartz, J.B. Pharmacokinetics of Calcium Antagonists Under Development. Clin-Pharmacokinet 15, 1–14 (1988). https://doi.org/10.2165/00003088-198815010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198815010-00001

Keywords

Search

Navigation